<DOC>
	<DOCNO>NCT00427726</DOCNO>
	<brief_summary>This study provide follow-up evaluation breast cancer multiple myeloma patient receive gene therapy ( gene transfer ) part participation NIH protocol . Gene therapy new technology , may involve permanent change patient genetic code . Therefore , although risk long-term harmful effect therapy small , Food Drug Administration require prolonged monitoring patient health status . Patients previously enrol NIH protocol 96-C-0007 , 93-C-0208 , 92-C-0161 , 92-H-0057 follow current protocol . No gene therapy provide study . Patients health status evaluate indefinite period time , long willing monitor . They provide blood sample year interview health status twice year first 5 year gene therapy year thereafter . These procedure do look development disease cancer , neurological disorder , autoimmune blood disorder may relate side effect gene transfer .</brief_summary>
	<brief_title>Follow-up Breast Cancer Multiple Myeloma Patients Previously Enrolled NIH Gene Therapy Studies</brief_title>
	<detailed_description>This Protocol aim provide long-term follow-up breast cancer multiple myeloma subject previously receive autologous primitive marrow blood hematopoietic cell expose gene transfer retroviral vector follow protocol : MB 294 ( 92-C-0161 ; T-92-0018 ) , MB 310 ( 93-C-0208 ; T-92-0192 ) , MB 361 ( 96-C-0007 ; T-95-0096 ) ( 92-H-0057 ; T-92-0139 ) National Cancer Institute National Heart , Lung , Blood Institute . Subjects undergo annual health history annual complete blood count perform . Blood sample also collect annually ( either locally off-site subject ' personal physician ) test presence gene transfer vector vector integration site .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects receive gene transfer product follow protocol : MB 361 , 96C0007 , T950096 ; MB 294 , 92C0161 , T920018 ; MB 310 , 93C 0208 , T920192 ; 92H0057 , T920139 . EXCLUSION CRITERIA : Patients unwilling participate .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 20, 2014</verification_date>
	<keyword>Gene Transfer</keyword>
	<keyword>Hematopoietic Stem Cells</keyword>
	<keyword>Follow-Up</keyword>
</DOC>